ReviewLiver research (Beijing, China)2023
Hepatocellular carcinoma recurrence: Predictors and management.
Review in Liver research (Beijing, China), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Circulating tumour DNA for a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: a systematic review and meta-analysis.British journal of cancer · 2026Pooled it
- Narrow-margin hepatectomy combined with external beam radiotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Article
- Emerging Immune-Based Therapeutic Strategies in Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- 3D HepG2 spheroid model exhibits drug-specific response profiles validating their application in therapeutic screening.In vitro cellular & developmental biology. Animal · 2026Article
- Preoperative Total Iron-Binding Capacity Is a Novel Surrogate Marker of Short- and Long-Term Outcomes After Liver Resection for Hepatocellular Carcinoma.Annals of gastroenterological surgery · 2026Article
- Evaluation of anticancer activity of beta glucan in non-alcoholic steatohepatitis associated hepatocellular carcinoma in rats.Cancer chemotherapy and pharmacology · 2026Article
- Economic Burden of Recurrence in Early-Stage Hepatocellular Carcinoma Treated with Surgical Resection or Local Ablation in the United States: A Retrospective Analysis of Surveillance, Epidemiology and End Results-Medicare Data.Advances in therapy · 2026Article
- Emerging role of proteomics in advancing diagnosis, prognosis, and treatment of liver cancer.Liver research (Beijing, China) · 2026Review
- Hepatitis C virus core promotes hepatic cancer stem cell formation via β-catenin-mediated EpCAM upregulation.Microbiology spectrum · 2026Article
- Are 2D MRI slices equally important in microvascular invasion prediction: a study based on multiple instance learning with attention.BMC medical imaging · 2026Article
- Matrix stiffness-induced YEATS2 drives HCC progression via epigenetic activation of the TGFBR2-TAZ-AKT pathway.Cell death and differentiation · 2026Article
- Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.Liver research (Beijing, China) · 2026Review
- Exosomal microRNA-448 suppresses the malignant behaviors of liver cancer cells by targeting RAB7A and inhibiting glycolysis.Oncology letters · 2026Article
- Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives.Vaccines · 2026Review
- Cinobufagin as a Potential Intervention Against Liver Cancer-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Role of TARE for Bridging and Downstaging of HCC Before Resection or Liver Transplant.Cancers · 2026Article
- Analysis of survival prognosis and influencing factors in patients with primary liver cancer after D-TACE: a retrospective cohort study.BMC gastroenterology · 2026Article
- TMEM160 promotes hepatocellular carcinoma cell proliferation, invasion, and immune evasion by regulating the VEGFA/PI3K/AKT signaling axis.Frontiers in immunology · 2026Article
- Machine-Learning Based Prognostic Model for Predicting Early Recurrence in HCC Patients After Hepatectomies: An Explainable AI Approach.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), the sixth most common cancer globally, is associated with high mortality rates and more than 830,000 annual deaths. Despite advances in the available management options including surgical resection and local ablative therapies, recurrence rates after the initial treatment exceed 50%, even among patients who have undergone curative-intent therapy. Moreover, postsurgical HCC recurrence occurs in about 70% of cases five years postoperatively. The management of recurrent HCC remains undefined. This review discusses different predictors for HCC recurrence after each treatment modality and different approaches available to stratify these patients. More specific guidelines for managing HCC recurrence and strict surveillance protocols for such recurrence after initial HCC management are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.